New England Journal of Medicine· 2013Q1

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg et al.

3,483citations
Q1SCImago
2013year

Short summary

Saxagliptin, a DPP-4 inhibitor, did not increase or decrease ischemic cardiovascular events (MI, stroke, CV death) in patients with type 2 diabetes, but it did increase heart failure hospitalizations (3.5% vs 2.8%).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine